Tamiflu Found to Be Ineffective, May Increase Mortality in Patients Critically Ill With Influenza
A randomized clinical trial posted as a preprint on July 27, 2026, found that treatment with oseltamivir, commonly known by the brand name Tamiflu, is not only ineffective, but highly likely to increase 90-day mortality in critically ill patients with influenza. Researchers enrolled 442 critically ill patients aged 12 and older with laboratory-confirmed influenza between […]
mRNA, Spike Proteins Persist in the Human Body for More Than 3.5 Years After COVID-19 Shots
A newly published case report in Medical Research Archives found that vaccine-derived synthetic mRNA, spike protein and plasmid DNA sequences persisted in the blood and tissue of a 55-year-old man more than three years after his last Pfizer mRNA COVID-19 shot, with some components detected beyond the 3.5-year mark. The case report, published July 1, […]
Despite Safety Concerns, FDA Approves Moderna’s mRNA Flu Shot
On Aug. 5, 2026, the U.S. Food and Drug Administration (FDA) approved Moderna’s seasonal flu shot, mFLUSIVA (mRNA-1010), making it the first messenger RNA platform for seasonal influenza in the United States. The decision permits health care providers to use mRNA technology for annual influenza vaccination in eligible age groups.1 FDA regulators approved mFLUSIVA to […]
WHO Report Projects Cancer Cases Will Nearly Double Worldwide by 2050
The World Health Organization (WHO) Global Status Report on Cancer 2026, released on July 8, 2026, projects that, without urgent action, new annual cancer cases will nearly double, from the current 20.6 million to nearly 35 million by 2050. While heart disease remains the leading cause of death worldwide, cancer ranks second. The WHO attributes […]
FDA Flags Manufacturing Issues at Biologics Facility in India
The U.S. Food and Drug Administration (FDA) has flagged violations at a large manufacturing facility in India, which distributes biologics and drugs in the United States. The FDA issued a Form 483 with seven inspection observations following a recent review of Dr. Reddy’s Laboratories, a biologics manufacturing facility in Bachupally, Hyderabad, India. The agency has […]
FDA Leadership’s “Blind Spots” Lead to a Surge in Medical Device and Drug Recalls
Americans assume that when they pick up a prescription from their pharmacy, an FDA quality control professional has verified that the contents are manufactured to rigorous agency standards. Unfortunately, that assumption is becoming harder to defend. For decades, the FDA’s drug oversight model has depended on in-person inspections of the manufacturing practice and independent verification […]